Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;63(3):315-322.
doi: 10.5468/ogs.2020.63.3.315. Epub 2020 Apr 21.

Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial

Rahul Vishwanath Mayekar  1 , Gopalkrishna Vinayak Paradkar  2 , Archana Anilkumar Bhosale  1 , Rekha Sachan  3 , Sumalatha Beeram  4 , Ashok Ramachandra Anand  5 , Shuchita Ramesh Mundle  6 , Yamini Trivedi  7 , Rashmi Md  8 , Kiran Pandharinath Patole  9 , Pradip Wamanrao Sambarey  10 , Gautam Vinod Daftary  11 , James John  11 , Ganesh Harishchandra Divekar  11
Affiliations

Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial

Rahul Vishwanath Mayekar et al. Obstet Gynecol Sci. 2020 May.

Abstract

Objective: To compare the efficacy and safety of recombinant anti-D (R-anti-D) with conventional polyclonal anti-D (Poly anti-D) in preventing maternal-fetal rhesus D (RhD) alloimmunization and to investigate the immunogenicity of R-anti-D.

Methods: This was a randomized, open-label, multi-center clinical trial conducted in RhD-negative pregnant women who did not receive antenatal anti-D who delivered RhD-positive babies and showed negative indirect Coombs tests (ICTs) at baseline. The women were randomized in a 2:1 ratio to R-anti-D or Poly anti-D groups and were administered 300 mcg (IM) of the corresponding drug within 72 hours of delivery. ICT was performed 72 hours, 90 days, and 180 days after anti-D injection. Serum samples were collected to check for the development of antibodies against R-anti-D at days 90 and 180, using bridging enzyme-linked immunosorbent assay. The proportion of subjects who had positive ICT results at days 90 and 180 were compared between the groups using Fisher's exact test.

Results: A total of 144 women were randomized to the R-anti-D group and 71 to the Poly anti-D group. Three women in the R-anti-D and none in the Poly anti-D group had a positive ICT result at day 90. No woman in either group had positive ICT result at day 180. Both drugs were well tolerated with only 4 reports of adverse events in each group-all were mild, non-serious, and resolved without sequelae. No subject developed antibodies against R-anti-D.

Conclusion: The studied R-anti-D is comparable in efficacy to conventional Poly anti-D and is safe and non-immunogenic.Trial Registration: Clinical Trials Registry of India Identifier: Trial Registration: Clinical Trials Registry of India Identifier: CTRI/2017/03/008101.

Keywords: Newborn hemolytic disease; Recombinant proteins; Rh isoimmunization; Rho(D) immune globulin.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The author Gautam Vinod Daftary is the managing director at Bharat Serums and Vaccines Limited. The authors James John and Ganesh Harishchandra Divekar are full-time paid employees of Bharat Serums and Vaccines Limited.

Figures

Fig. 1
Fig. 1. Manufacturing process and link between monoclonal anti-D (Rhoclone®) and recombinant anti-D.
Fig. 2
Fig. 2. Principle of biotin-digoxigenin complex-based bridging ELISA to test the immunogenicity of R-anti-D.
ADA, antidrug antibody; R-anti-D, recombinant anti-D; HRP, horseradish peroxidase; TMB, tetramethylbenzidine; ELISA, enzyme-linked immunosorbent assay.
Fig. 3
Fig. 3. Trial and participant flow. One subject from the R-anti-D group and 4 subjects from the Poly anti-D group were excluded from efficacy analysis owing to major protocol deviations.
R-anti-D, recombinant anti-D; Poly anti-D, polyclonal anti-D; F/U, followed-up.
See this image and copyright information in PMC

References

    1. Bennardello F, Coluzzi S, Curciarello G, Todros T, Villa S Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) and Italian Society of Gynaecology and Obstetrics (SIGO) working group. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. Blood Transfus. 2015;13:109–134. - PMC - PubMed
    1. Zimring JC, Hudson KE. Cellular immune responses in red blood cell alloimmunization. Hematology Am Soc Hematol Educ Program. 2016;2016:452–456. - PMC - PubMed
    1. Agarwal K, Rana A, Ravi AK. Treatment and prevention of Rh isoimmunization. J Fetal Med. 2014;1:81–88.
    1. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. 2015;2015:146–151. - PubMed
    1. Qureshi H, Massey E, Kirwan D, Davies T, Robson S, White J, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med. 2014;24:8–20. - PubMed